Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis
Background: The pollen of Parietaria spp., a weed of the Urticaceae family, is a major cause of respiratory allergy in the Mediterranean area, where the most common species are Parietaria judaica and Parietaria officinalis. In this study, we evaluated the specific serum IgE-binding profiles to indiv...
Gespeichert in:
Veröffentlicht in: | International Archives of Allergy and Immunology 2005-10, Vol.138 (2), p.105-110 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 110 |
---|---|
container_issue | 2 |
container_start_page | 105 |
container_title | International Archives of Allergy and Immunology |
container_volume | 138 |
creator | Rossi, R.E. Monasterolo, G. Coco, G. Operti, D. |
description | Background: The pollen of Parietaria spp., a weed of the Urticaceae family, is a major cause of respiratory allergy in the Mediterranean area, where the most common species are Parietaria judaica and Parietaria officinalis. In this study, we evaluated the specific serum IgE-binding profiles to individual P. judaica pollen recombinant major allergen, and Phleum pratense cytoskeletal profilin and a 2-EF-hand calcium-binding allergen homologous to cross-reactive Parietaria pollen allergens, in patients allergic to pollen with positive skin test towards Parietaria spp. extract. Methods: The present observation included 220 patients from the province of Cuneo, north-west Italy, all suffering from rhino-conjunctivitis and/or asthma selected on the basis of skin test positive to P. judaica extract. The sera were evaluated for specific IgE reactivity to P. judaica pollen major recombinant(r) allergen Par j 2, Phleum pratense pollen allergens rPhl p 7 (2-EF-hand calcium binding protein) and rPhl p 12 (profilin), both identified as cross-reactive Parietaria spp. allergens, using Pharmacia CAP System. Out of 220 patients, 37 patients with IgE reactivity to rPar j 2 and 105 patients sensitized to at least one timothy pollen major allergen (i. e. rPhl p 1, rPhl p 2, natural Phl p 4 and rPhl p 6) were submitted to an ultra-rush protocol of sublingual immunotherapy (SLIT). The occurrence of adverse reactions were evaluated in both groups. Results: All 220 patients with pollinosis and positive in vivo skin prick tests had in vitro positive CAP results to P. judaica natural extract. On the contrary, in these patients the prevalence of Par j 2-specific IgE was only 33.2% (73/220). In fact, 116/220 (52.7%) patients with serum specific IgE to crude Parietaria pollen extract had specific IgE to Phl p 12, 18/220 (8.1%) subjects with specific IgE to rPhl p 12 also exhibited specific IgE to Phl p 7 and 26/220 (11.8%) subjects had specific IgE against rPhl p 7. Particularly, geometric mean (25th–75th percentile) of specific IgE to rPar j 2 were as follows: 2.87 kUA/l (1.005–7.465). Out of 73 patients with specific IgE to rPar j 2, 7 subjects (9.6%) had also specific IgE to rPhl p 7, 12 (16.4%) had specific IgE to rPhl p 12 and 4 (4.1%) patients had specific IgE to both recombinant allergens. Of 37 patients under an ultra-rush protocol of SLIT, 3 subjects (8.1%) experienced generalized urticaria, and 1 of them also had diarrhea 3 h after the last dose of Parietaria judaica extract |
doi_str_mv | 10.1159/000088431 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20840082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>919107991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-200f6e362016df85e490b2a5b7a1b9b9bce35847a0ecb224e733061254b3a4f03</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEoqVw4IyELCQQPQT8tYlzrJYClSqx6tJz5CSTXS-OHWwHtPxKfhKzbNRKXLAPtuznfcfjmSx7zug7xhbVe4pDKSnYg-yUSS5ySqvyIe4pUzmXQp1kT2LcUYqwKh5nJ6xgpaxUeZr9XvkYTWOB3IDVyXgXt2YkDaSfAI6s9zHBYFqyNh2Qy76HNkWiXUfW4KJJ5tdfDUmehJUOZEc4MY5cWAthg7IVXoNDyXpqBpMSdAdUO3JrU9D5zRS35C2nZDDu_MBY4zaTtuRqGCbn0xaCHvdzPIuxUd_sydIPo3foi4-O3v7A0w9Gb5yPJj7NHvXaRng2r2fZ7cfLr8vP-fWXT1fLi-u8FRVLOae0L0AUnLKi69UCZEUbrhdNqVlT4WxBLJQsNYW24VxCKQQtGF_IRmjZU3GWvTn6jsF_nyCmejCxBWu1Az_FulClKHml_gtyqiSWjyP46h9w56fgMImac6YoL8XB7fwItQELF6Cvx2AGHfY1o_WhGeq7ZkD25WyInw_dPTlXH4HXM6Bjq20ftGtNvOdKTLygErkXR-6bDhsId8AxzB-Qk8Yc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221802738</pqid></control><display><type>article</type><title>Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis</title><source>IngentaConnect</source><source>Open Access: PubMed Central</source><source>Karger Journals</source><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Online Library Free Content</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Rossi, R.E. ; Monasterolo, G. ; Coco, G. ; Operti, D.</creator><creatorcontrib>Rossi, R.E. ; Monasterolo, G. ; Coco, G. ; Operti, D.</creatorcontrib><description>Background: The pollen of Parietaria spp., a weed of the Urticaceae family, is a major cause of respiratory allergy in the Mediterranean area, where the most common species are Parietaria judaica and Parietaria officinalis. In this study, we evaluated the specific serum IgE-binding profiles to individual P. judaica pollen recombinant major allergen, and Phleum pratense cytoskeletal profilin and a 2-EF-hand calcium-binding allergen homologous to cross-reactive Parietaria pollen allergens, in patients allergic to pollen with positive skin test towards Parietaria spp. extract. Methods: The present observation included 220 patients from the province of Cuneo, north-west Italy, all suffering from rhino-conjunctivitis and/or asthma selected on the basis of skin test positive to P. judaica extract. The sera were evaluated for specific IgE reactivity to P. judaica pollen major recombinant(r) allergen Par j 2, Phleum pratense pollen allergens rPhl p 7 (2-EF-hand calcium binding protein) and rPhl p 12 (profilin), both identified as cross-reactive Parietaria spp. allergens, using Pharmacia CAP System. Out of 220 patients, 37 patients with IgE reactivity to rPar j 2 and 105 patients sensitized to at least one timothy pollen major allergen (i. e. rPhl p 1, rPhl p 2, natural Phl p 4 and rPhl p 6) were submitted to an ultra-rush protocol of sublingual immunotherapy (SLIT). The occurrence of adverse reactions were evaluated in both groups. Results: All 220 patients with pollinosis and positive in vivo skin prick tests had in vitro positive CAP results to P. judaica natural extract. On the contrary, in these patients the prevalence of Par j 2-specific IgE was only 33.2% (73/220). In fact, 116/220 (52.7%) patients with serum specific IgE to crude Parietaria pollen extract had specific IgE to Phl p 12, 18/220 (8.1%) subjects with specific IgE to rPhl p 12 also exhibited specific IgE to Phl p 7 and 26/220 (11.8%) subjects had specific IgE against rPhl p 7. Particularly, geometric mean (25th–75th percentile) of specific IgE to rPar j 2 were as follows: 2.87 kUA/l (1.005–7.465). Out of 73 patients with specific IgE to rPar j 2, 7 subjects (9.6%) had also specific IgE to rPhl p 7, 12 (16.4%) had specific IgE to rPhl p 12 and 4 (4.1%) patients had specific IgE to both recombinant allergens. Of 37 patients under an ultra-rush protocol of SLIT, 3 subjects (8.1%) experienced generalized urticaria, and 1 of them also had diarrhea 3 h after the last dose of Parietaria judaica extract oral-vaccine administration. On the contrary, no systemic reactions were observed in 105 patients after Phleum pratense extract oral intake after a similar ultra-rush SLIT protocol (p = 0.0046). Conclusions: In the light of present findings, allergen extract-based diagnosis, in vivo and in vitro, cannot discriminate allergic patients that are genuinely sensitized to Parietaria spp. major allergens or to other major allergens to which current immunotherapeutic allergy extracts are standardized. Therefore, in vitro component resolved diagnosis is the unique tool to define the disease eliciting molecule(s). Finally, during sublingual immunotherapy, not only the dose of allergen, but also the biochemical characteristic of the major allergen administered may be an important factor in determining possible systemic reactions.</description><identifier>ISSN: 1018-2438</identifier><identifier>EISSN: 1423-0097</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1159/000088431</identifier><identifier>PMID: 16174987</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Administration, Sublingual ; Adult ; Allergens - adverse effects ; Allergens - immunology ; Allergens - therapeutic use ; Allergies ; Antigens, Plant - adverse effects ; Antigens, Plant - immunology ; Antigens, Plant - therapeutic use ; Biological and medical sciences ; Cross Reactions ; Desensitization, Immunologic - adverse effects ; Drug therapy ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunoglobulin E - blood ; Immunology ; Immunopathology ; Male ; Medical diagnosis ; Medical sciences ; Middle Aged ; Original Paper ; Parietaria - chemistry ; Parietaria - immunology ; Parietaria judaica ; Parietaria officinalis ; Phleum - chemistry ; Phleum - immunology ; Phleum pratense ; Plant Extracts - adverse effects ; Plant Extracts - immunology ; Plant Proteins - adverse effects ; Plant Proteins - immunology ; Plant Proteins - therapeutic use ; Pollen ; Pollen - immunology ; Proteins ; Rhinitis, Allergic, Seasonal - diagnosis ; Rhinitis, Allergic, Seasonal - drug therapy ; Side effects ; Urticaceae</subject><ispartof>International Archives of Allergy and Immunology, 2005-10, Vol.138 (2), p.105-110</ispartof><rights>2005 S. Karger AG, Basel</rights><rights>2005 INIST-CNRS</rights><rights>(c) 2005 S. Karger AG, Basel</rights><rights>Copyright (c) 2005 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-200f6e362016df85e490b2a5b7a1b9b9bce35847a0ecb224e733061254b3a4f03</citedby><cites>FETCH-LOGICAL-c391t-200f6e362016df85e490b2a5b7a1b9b9bce35847a0ecb224e733061254b3a4f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17224604$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16174987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rossi, R.E.</creatorcontrib><creatorcontrib>Monasterolo, G.</creatorcontrib><creatorcontrib>Coco, G.</creatorcontrib><creatorcontrib>Operti, D.</creatorcontrib><title>Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis</title><title>International Archives of Allergy and Immunology</title><addtitle>Int Arch Allergy Immunol</addtitle><description>Background: The pollen of Parietaria spp., a weed of the Urticaceae family, is a major cause of respiratory allergy in the Mediterranean area, where the most common species are Parietaria judaica and Parietaria officinalis. In this study, we evaluated the specific serum IgE-binding profiles to individual P. judaica pollen recombinant major allergen, and Phleum pratense cytoskeletal profilin and a 2-EF-hand calcium-binding allergen homologous to cross-reactive Parietaria pollen allergens, in patients allergic to pollen with positive skin test towards Parietaria spp. extract. Methods: The present observation included 220 patients from the province of Cuneo, north-west Italy, all suffering from rhino-conjunctivitis and/or asthma selected on the basis of skin test positive to P. judaica extract. The sera were evaluated for specific IgE reactivity to P. judaica pollen major recombinant(r) allergen Par j 2, Phleum pratense pollen allergens rPhl p 7 (2-EF-hand calcium binding protein) and rPhl p 12 (profilin), both identified as cross-reactive Parietaria spp. allergens, using Pharmacia CAP System. Out of 220 patients, 37 patients with IgE reactivity to rPar j 2 and 105 patients sensitized to at least one timothy pollen major allergen (i. e. rPhl p 1, rPhl p 2, natural Phl p 4 and rPhl p 6) were submitted to an ultra-rush protocol of sublingual immunotherapy (SLIT). The occurrence of adverse reactions were evaluated in both groups. Results: All 220 patients with pollinosis and positive in vivo skin prick tests had in vitro positive CAP results to P. judaica natural extract. On the contrary, in these patients the prevalence of Par j 2-specific IgE was only 33.2% (73/220). In fact, 116/220 (52.7%) patients with serum specific IgE to crude Parietaria pollen extract had specific IgE to Phl p 12, 18/220 (8.1%) subjects with specific IgE to rPhl p 12 also exhibited specific IgE to Phl p 7 and 26/220 (11.8%) subjects had specific IgE against rPhl p 7. Particularly, geometric mean (25th–75th percentile) of specific IgE to rPar j 2 were as follows: 2.87 kUA/l (1.005–7.465). Out of 73 patients with specific IgE to rPar j 2, 7 subjects (9.6%) had also specific IgE to rPhl p 7, 12 (16.4%) had specific IgE to rPhl p 12 and 4 (4.1%) patients had specific IgE to both recombinant allergens. Of 37 patients under an ultra-rush protocol of SLIT, 3 subjects (8.1%) experienced generalized urticaria, and 1 of them also had diarrhea 3 h after the last dose of Parietaria judaica extract oral-vaccine administration. On the contrary, no systemic reactions were observed in 105 patients after Phleum pratense extract oral intake after a similar ultra-rush SLIT protocol (p = 0.0046). Conclusions: In the light of present findings, allergen extract-based diagnosis, in vivo and in vitro, cannot discriminate allergic patients that are genuinely sensitized to Parietaria spp. major allergens or to other major allergens to which current immunotherapeutic allergy extracts are standardized. Therefore, in vitro component resolved diagnosis is the unique tool to define the disease eliciting molecule(s). Finally, during sublingual immunotherapy, not only the dose of allergen, but also the biochemical characteristic of the major allergen administered may be an important factor in determining possible systemic reactions.</description><subject>Administration, Sublingual</subject><subject>Adult</subject><subject>Allergens - adverse effects</subject><subject>Allergens - immunology</subject><subject>Allergens - therapeutic use</subject><subject>Allergies</subject><subject>Antigens, Plant - adverse effects</subject><subject>Antigens, Plant - immunology</subject><subject>Antigens, Plant - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cross Reactions</subject><subject>Desensitization, Immunologic - adverse effects</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Immunology</subject><subject>Immunopathology</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Parietaria - chemistry</subject><subject>Parietaria - immunology</subject><subject>Parietaria judaica</subject><subject>Parietaria officinalis</subject><subject>Phleum - chemistry</subject><subject>Phleum - immunology</subject><subject>Phleum pratense</subject><subject>Plant Extracts - adverse effects</subject><subject>Plant Extracts - immunology</subject><subject>Plant Proteins - adverse effects</subject><subject>Plant Proteins - immunology</subject><subject>Plant Proteins - therapeutic use</subject><subject>Pollen</subject><subject>Pollen - immunology</subject><subject>Proteins</subject><subject>Rhinitis, Allergic, Seasonal - diagnosis</subject><subject>Rhinitis, Allergic, Seasonal - drug therapy</subject><subject>Side effects</subject><subject>Urticaceae</subject><issn>1018-2438</issn><issn>1423-0097</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhiMEoqVw4IyELCQQPQT8tYlzrJYClSqx6tJz5CSTXS-OHWwHtPxKfhKzbNRKXLAPtuznfcfjmSx7zug7xhbVe4pDKSnYg-yUSS5ySqvyIe4pUzmXQp1kT2LcUYqwKh5nJ6xgpaxUeZr9XvkYTWOB3IDVyXgXt2YkDaSfAI6s9zHBYFqyNh2Qy76HNkWiXUfW4KJJ5tdfDUmehJUOZEc4MY5cWAthg7IVXoNDyXpqBpMSdAdUO3JrU9D5zRS35C2nZDDu_MBY4zaTtuRqGCbn0xaCHvdzPIuxUd_sydIPo3foi4-O3v7A0w9Gb5yPJj7NHvXaRng2r2fZ7cfLr8vP-fWXT1fLi-u8FRVLOae0L0AUnLKi69UCZEUbrhdNqVlT4WxBLJQsNYW24VxCKQQtGF_IRmjZU3GWvTn6jsF_nyCmejCxBWu1Az_FulClKHml_gtyqiSWjyP46h9w56fgMImac6YoL8XB7fwItQELF6Cvx2AGHfY1o_WhGeq7ZkD25WyInw_dPTlXH4HXM6Bjq20ftGtNvOdKTLygErkXR-6bDhsId8AxzB-Qk8Yc</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Rossi, R.E.</creator><creator>Monasterolo, G.</creator><creator>Coco, G.</creator><creator>Operti, D.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis</title><author>Rossi, R.E. ; Monasterolo, G. ; Coco, G. ; Operti, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-200f6e362016df85e490b2a5b7a1b9b9bce35847a0ecb224e733061254b3a4f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Sublingual</topic><topic>Adult</topic><topic>Allergens - adverse effects</topic><topic>Allergens - immunology</topic><topic>Allergens - therapeutic use</topic><topic>Allergies</topic><topic>Antigens, Plant - adverse effects</topic><topic>Antigens, Plant - immunology</topic><topic>Antigens, Plant - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cross Reactions</topic><topic>Desensitization, Immunologic - adverse effects</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Immunology</topic><topic>Immunopathology</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Parietaria - chemistry</topic><topic>Parietaria - immunology</topic><topic>Parietaria judaica</topic><topic>Parietaria officinalis</topic><topic>Phleum - chemistry</topic><topic>Phleum - immunology</topic><topic>Phleum pratense</topic><topic>Plant Extracts - adverse effects</topic><topic>Plant Extracts - immunology</topic><topic>Plant Proteins - adverse effects</topic><topic>Plant Proteins - immunology</topic><topic>Plant Proteins - therapeutic use</topic><topic>Pollen</topic><topic>Pollen - immunology</topic><topic>Proteins</topic><topic>Rhinitis, Allergic, Seasonal - diagnosis</topic><topic>Rhinitis, Allergic, Seasonal - drug therapy</topic><topic>Side effects</topic><topic>Urticaceae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rossi, R.E.</creatorcontrib><creatorcontrib>Monasterolo, G.</creatorcontrib><creatorcontrib>Coco, G.</creatorcontrib><creatorcontrib>Operti, D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International Archives of Allergy and Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rossi, R.E.</au><au>Monasterolo, G.</au><au>Coco, G.</au><au>Operti, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis</atitle><jtitle>International Archives of Allergy and Immunology</jtitle><addtitle>Int Arch Allergy Immunol</addtitle><date>2005-10</date><risdate>2005</risdate><volume>138</volume><issue>2</issue><spage>105</spage><epage>110</epage><pages>105-110</pages><issn>1018-2438</issn><eissn>1423-0097</eissn><eissn>1365-2567</eissn><abstract>Background: The pollen of Parietaria spp., a weed of the Urticaceae family, is a major cause of respiratory allergy in the Mediterranean area, where the most common species are Parietaria judaica and Parietaria officinalis. In this study, we evaluated the specific serum IgE-binding profiles to individual P. judaica pollen recombinant major allergen, and Phleum pratense cytoskeletal profilin and a 2-EF-hand calcium-binding allergen homologous to cross-reactive Parietaria pollen allergens, in patients allergic to pollen with positive skin test towards Parietaria spp. extract. Methods: The present observation included 220 patients from the province of Cuneo, north-west Italy, all suffering from rhino-conjunctivitis and/or asthma selected on the basis of skin test positive to P. judaica extract. The sera were evaluated for specific IgE reactivity to P. judaica pollen major recombinant(r) allergen Par j 2, Phleum pratense pollen allergens rPhl p 7 (2-EF-hand calcium binding protein) and rPhl p 12 (profilin), both identified as cross-reactive Parietaria spp. allergens, using Pharmacia CAP System. Out of 220 patients, 37 patients with IgE reactivity to rPar j 2 and 105 patients sensitized to at least one timothy pollen major allergen (i. e. rPhl p 1, rPhl p 2, natural Phl p 4 and rPhl p 6) were submitted to an ultra-rush protocol of sublingual immunotherapy (SLIT). The occurrence of adverse reactions were evaluated in both groups. Results: All 220 patients with pollinosis and positive in vivo skin prick tests had in vitro positive CAP results to P. judaica natural extract. On the contrary, in these patients the prevalence of Par j 2-specific IgE was only 33.2% (73/220). In fact, 116/220 (52.7%) patients with serum specific IgE to crude Parietaria pollen extract had specific IgE to Phl p 12, 18/220 (8.1%) subjects with specific IgE to rPhl p 12 also exhibited specific IgE to Phl p 7 and 26/220 (11.8%) subjects had specific IgE against rPhl p 7. Particularly, geometric mean (25th–75th percentile) of specific IgE to rPar j 2 were as follows: 2.87 kUA/l (1.005–7.465). Out of 73 patients with specific IgE to rPar j 2, 7 subjects (9.6%) had also specific IgE to rPhl p 7, 12 (16.4%) had specific IgE to rPhl p 12 and 4 (4.1%) patients had specific IgE to both recombinant allergens. Of 37 patients under an ultra-rush protocol of SLIT, 3 subjects (8.1%) experienced generalized urticaria, and 1 of them also had diarrhea 3 h after the last dose of Parietaria judaica extract oral-vaccine administration. On the contrary, no systemic reactions were observed in 105 patients after Phleum pratense extract oral intake after a similar ultra-rush SLIT protocol (p = 0.0046). Conclusions: In the light of present findings, allergen extract-based diagnosis, in vivo and in vitro, cannot discriminate allergic patients that are genuinely sensitized to Parietaria spp. major allergens or to other major allergens to which current immunotherapeutic allergy extracts are standardized. Therefore, in vitro component resolved diagnosis is the unique tool to define the disease eliciting molecule(s). Finally, during sublingual immunotherapy, not only the dose of allergen, but also the biochemical characteristic of the major allergen administered may be an important factor in determining possible systemic reactions.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>16174987</pmid><doi>10.1159/000088431</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1018-2438 |
ispartof | International Archives of Allergy and Immunology, 2005-10, Vol.138 (2), p.105-110 |
issn | 1018-2438 1423-0097 1365-2567 |
language | eng |
recordid | cdi_proquest_miscellaneous_20840082 |
source | IngentaConnect; Open Access: PubMed Central; Karger Journals; MEDLINE; Wiley Online Library; Wiley Online Library Free Content; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Administration, Sublingual Adult Allergens - adverse effects Allergens - immunology Allergens - therapeutic use Allergies Antigens, Plant - adverse effects Antigens, Plant - immunology Antigens, Plant - therapeutic use Biological and medical sciences Cross Reactions Desensitization, Immunologic - adverse effects Drug therapy Female Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunoglobulin E - blood Immunology Immunopathology Male Medical diagnosis Medical sciences Middle Aged Original Paper Parietaria - chemistry Parietaria - immunology Parietaria judaica Parietaria officinalis Phleum - chemistry Phleum - immunology Phleum pratense Plant Extracts - adverse effects Plant Extracts - immunology Plant Proteins - adverse effects Plant Proteins - immunology Plant Proteins - therapeutic use Pollen Pollen - immunology Proteins Rhinitis, Allergic, Seasonal - diagnosis Rhinitis, Allergic, Seasonal - drug therapy Side effects Urticaceae |
title | Possible Relationship between Systemic Side Effects and Sensitization to rPar j 2 in Allergic Patients Submitted to an Ultra-Rush (20 min) Sublingual Immunotherapy and Selected by Component Resolved Diagnosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A27%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20Relationship%20between%20Systemic%20Side%20Effects%20and%20Sensitization%20to%20rPar%20j%202%20in%20Allergic%20Patients%20Submitted%20to%20an%20Ultra-Rush%20(20%20min)%20Sublingual%20Immunotherapy%20and%20Selected%20by%20Component%20Resolved%20Diagnosis&rft.jtitle=International%20Archives%20of%20Allergy%20and%20Immunology&rft.au=Rossi,%20R.E.&rft.date=2005-10&rft.volume=138&rft.issue=2&rft.spage=105&rft.epage=110&rft.pages=105-110&rft.issn=1018-2438&rft.eissn=1423-0097&rft_id=info:doi/10.1159/000088431&rft_dat=%3Cproquest_cross%3E919107991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221802738&rft_id=info:pmid/16174987&rfr_iscdi=true |